MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Evaluation of Parkinson’s Disease Psychosis Requires Structured Questioning of Patients and Caregivers

    P. Schmidt, F. Cubillos, A. Diaz, P. Wiener, S. Metz, N. Romero, C. Andersson, S. Andes, D. Fredericks, A. Shim (Miami, FL, USA)

    Objective: To determine the relationship between the patient and caregiver experience of the psychotic features of Parkinson's disease psychosis (PDP) reported to call center healthcare…
  • 2018 International Congress

    What can we learn from fMRI capture of visual hallucinations in Parkinson’s disease?

    K. Dujardin, D. Roman, G. Baille, D. Pins, S. Lefebvre, C. Delmaire, L. Defebvre, R. Jardri (Lille, France)

    Objective: To describe the patterns of brain functional changes when visual hallucinations (VH) occur in patients with Parkinson's disease (PD). Background: ​With disease progression, PD…
  • 2018 International Congress

    A Psychometric Analysis of the MDS UPDRS-II and III in Early Parkinson’s disease: Do the Numbers Add Up?

    A. Regnault, B. Boroodjerdi, J. Meunier, M. Bani, S. Cano (Lyon, France)

    Objective: Our objective was to explore the psychometric evidence for the use of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part II…
  • 2018 International Congress

    A German-Austrian multicenter, non-interventional, prospective study for the treatment with abobotulinumtoxinA injections in naïve and previously treated patients suffering from cervical dystonia

    W. Jost, A. Schramm, M. Müngersdorf, A. Stenner, P. Schwingenschuh, P. Maisonobe, M. Koch, B. Haslinger (Wolfach, Germany)

    Objective: In this prospective, multicenter, non-interventional study (NCT01840462) the primary objective was effectiveness of abobotulinumtoxinA in BoNT treatment-naïve and previously treated subjects after two injection…
  • 2018 International Congress

    Safinamide in Parkinson’s disease

    G. Martí-Andrés, R. Jiménez-Bolaños, J. Arbelo-González, J. Pagonabarraga-Mora, C. Duran-Herrera, M. Carmona-Abellán, R. Luquin-Puido (Pamplona, Spain)

    Objective: To evaluate clinical effects, safety and tolerability of safinamide add-on levodopa in Parkinson’s disease (PD) patients. Background: Safinamide is a recently approved adjunctive treatment…
  • « Previous Page
  • 1
  • …
  • 175
  • 176
  • 177

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley